6533b826fe1ef96bd128525b

RESEARCH PRODUCT

Spanish Menopause Society position statement: Use of denosumab in postmenopausal women

Antonio CanoJavier FerrerJosé VilleroFrancesc BaróRafael Sánchez-borregoFrancisco QueredaAntonio EstévezJosé Manuel SilvanNicolás Mendoza

subject

Position statementOncologymedicine.medical_specialtyInjections SubcutaneousOsteoporosisBone NeoplasmsBreast NeoplasmsGeneral Biochemistry Genetics and Molecular BiologyFractures BoneBreast cancerBone DensityInternal medicinemedicineHumansOsteoporosis PostmenopausalPostmenopausal womenBone Density Conservation Agentsbusiness.industryObstetrics and GynecologyCancerArea of interestmedicine.diseasePostmenopauseMenopauseDenosumabDisease ProgressionPhysical therapyFemaleBone RemodelingDenosumabSafetybusinessmedicine.drug

description

Denosumab is a new drug developed for the treatment of osteoporosis. Moreover, increasing evidences link denosumab with benefits in cancer, an area of interest for those in charge of the postmenopausal health. Denosumab has shown efficacy in the control of bone loss associated with hypogonadic states created by chemotherapy in breast and other cancers. Moreover, some studies reveal efficacy in reducing the progression of metastases. A panel of experts from the Spanish Menopause Society has met to develop usage recommendations based on the best available evidence.

yearjournalcountryeditionlanguage
2014-06-10Maturitas
https://doi.org/10.1016/j.maturitas.2014.06.011